MEDNAX Announces Closing of $500 Million of 6.250% Senior Notes Due 2027
MEDNAX, Inc. (NYSE:MD), announced today the closing of the previously announced private placement of $500 million aggregate
principal amount of its 6.250% senior notes due January 15, 2027 (the “Notes”). The completed transaction resulted in
approximately $492.5 million in net proceeds to MEDNAX, which will be used to repay a portion of the indebtedness outstanding under
its senior unsecured revolving credit facility. The Notes were offered to persons reasonably believed to be qualified institutional
buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United
States to persons other than U.S. persons in reliance upon Regulation S under the Securities Act.
This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not
constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. The
securities have not been registered under the Securities Act or any state securities laws, and unless so registered, may not be
offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and
applicable state laws.
ABOUT MEDNAX
MEDNAX, Inc. is a national health solutions partner comprised of the nation's leading providers of physician services.
Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and
subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telemedicine to enhance patient
outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated
professional corporations, MEDNAX provides services through a network of more than 4,200 physicians in all 50 states and Puerto
Rico. In addition to its national physician network, MEDNAX provides services to healthcare facilities and physicians in over 40
states through two complementary businesses, consisting of a management services company and a consulting services company.
Additional information is available at
www.mednax.com.
Forward-Looking Statements
Certain statements and information in this press release may be deemed to contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited
to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts,
that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the
future. These statements are often characterized by terminology such as “believe”, “hope”, “may”, “anticipate”, “should”, “intend”,
“plan”, “will”, “expect”, “estimate”, “project”, “positioned”, “strategy” and similar expressions, and are based on assumptions and
assessments made by MEDNAX’s management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release
are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to
risks and uncertainties and include the risks and uncertainties associated with market conditions. Important factors that could
cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in
MEDNAX’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk
Factors”, as well MEDNAX’s current reports on Form 8-K, filed with the Securities and Exchange Commission.
Charles Lynch
Vice President, Strategy and Investor Relations
954-384-0175, x-5692
charles_lynch@mednax.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113006209/en/